<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967443</url>
  </required_header>
  <id_info>
    <org_study_id>A0281006</org_study_id>
    <nct_id>NCT04967443</nct_id>
  </id_info>
  <brief_title>Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules</brief_title>
  <official_title>A 2 COHORT, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PIVOTAL BIOEQUIVALENCE STUDY TO QUALIFY MANUFACTURING SITE TRANSFER FROM BARCELONETA TO ASCOLI FOR PRAZOSIN HYDROCHLORIDE CAPSULES IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of&#xD;
      primary and secondary hypertension and heart failure. Pfizer Inc. is the marketing&#xD;
      authorization holder for prazosin HCl oral capsules and intended to transfer drug product&#xD;
      manufacturing operations from Pfizer, Barceloneta Puerto Rico to Pfizer Pharmaceutical,&#xD;
      Ascoli, Italy. To support the manufacturer site transfer and process changes, this&#xD;
      bioequivalence (BE) study is being conducted.&#xD;
&#xD;
      This study will be a 2 Cohort, open-label, randomized, single dose study in healthy adult&#xD;
      male and/or female participants. Cohort 1 will be crossover with 3 treatments, 3 periods, 6&#xD;
      sequences. Cohort 2 will be crossover with 2 treatments, 2 periods, 2 sequences. Primary&#xD;
      objective of this study is demonstrate bioequivalence between prazosin HCl 1, 2 and 5 mg&#xD;
      capsules manufactured at Ascoli versus prazosin HCl 2 and 5 mg capsules manufactured at&#xD;
      Barceloneta under fasting conditions in healthy adult participants. Approximately 36&#xD;
      participants will be enrolled in each Cohort 1 and Cohort 2.&#xD;
&#xD;
      Pharmacokinetic and statistical analysis will be performed for prazosin. Data from 2 Cohorts&#xD;
      will be analyzed separately. The PK parameters area under the plasma concentration-time curve&#xD;
      from time zero to the time of the last quantifiable concentration (AUClast), and from time&#xD;
      zero extrapolated to infinite time (AUCinf), maximum plasma concentration (Cmax), time to&#xD;
      first occurrence of Cmax (Tmax), and terminal phase elimination half-life (t½) will be&#xD;
      summarized descriptively by analyte and treatment.&#xD;
&#xD;
      For primary objective, bioequivalence of the Test treatment relative to Reference treatment&#xD;
      will be concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric&#xD;
      means of Test treatments relative to Reference treatment for AUCinf (if data permit), AUClast&#xD;
      and Cmax, fall wholly within (80%, 125%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">January 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Prazosin</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t 1/2)</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) According to Seriousness</measure>
    <time_frame>Baseline, up to 28 days post last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hypertension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 2 mg capsule manufactured at the current site, Barceloneta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prazosin HCL 2 mg capsule Ascoli site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 2 mg capsule manufactured at the proposed site (Ascoli)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prazosin HCL 1 mg capsule Ascoli site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 1 mg capsule manufactured at the proposed site, Ascoli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prazosin HCL 5 mg capsule Barceloneta site</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 5 mg capsule manufactured at the current site, Barceloneta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prazosin HCL 1 x 5 mg capsule Ascoli site</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 5 mg capsule manufactured at the proposed site, Ascoli</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin HCl 2mg</intervention_name>
    <description>Prazosin HCL 1 X 2 mg capsule.</description>
    <arm_group_label>Prazosin HCL 2 mg capsule Ascoli site</arm_group_label>
    <arm_group_label>Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site</arm_group_label>
    <other_name>Minipress 2 mg capsule.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin HCl 1 mg</intervention_name>
    <description>Prazosin HCl 2 X 1 mg capsule.</description>
    <arm_group_label>Prazosin HCL 1 mg capsule Ascoli site</arm_group_label>
    <other_name>Minipress 1 mg capsule.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin HCl 5 mg</intervention_name>
    <description>Prazosin HCL 1 X 5 mg capsule.</description>
    <arm_group_label>Prazosin HCL 1 x 5 mg capsule Ascoli site</arm_group_label>
    <arm_group_label>Prazosin HCL 5 mg capsule Barceloneta site</arm_group_label>
    <other_name>Minipress 5 mg capsule.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be 18 to 55 years of age, inclusive, at the time of signing the&#xD;
             Informed Consent Document (ICD).&#xD;
&#xD;
          -  Male and female participants who are overtly healthy as determined by medical&#xD;
             evaluation including medical history, full physical examination, vital signs, 12-lead&#xD;
             electrocardiogram (ECG), and/or clinical laboratory tests.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations , and other study procedures.&#xD;
&#xD;
          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in Appendix 1, which includes&#xD;
             compliance with the requirements and restrictions listed in the ICD and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (HIV) infection, hepatitis B, or hepatitis C;&#xD;
             positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B surface&#xD;
             antibody (HBsAb) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half lives (whichever is longer) prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  A positive urine drug test.&#xD;
&#xD;
          -  Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic),&#xD;
             following at least 5 minutes of supine rest.&#xD;
&#xD;
          -  Baseline standard 12 lead ECG that demonstrates clinically relevant abnormalities that&#xD;
             may affect participant safety or interpretation of study results.&#xD;
&#xD;
          -  Participants with ANY of the following abnormalities in clinical laboratory tests at&#xD;
             screening, as assessed by the study specific laboratory and confirmed by a single&#xD;
             repeat test, if deemed necessary:&#xD;
&#xD;
          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥1.5 × upper&#xD;
             limit of normal (ULN);&#xD;
&#xD;
          -  Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome&#xD;
             may have direct bilirubin measured and would be eligible for this study provided the&#xD;
             direct bilirubin level is ≤ ULN.&#xD;
&#xD;
          -  History of alcohol abuse or binge drinking and/or any other illicit drug use or&#xD;
             dependence within 6 months of Screening.&#xD;
&#xD;
          -  Use of tobacco or nicotine containing products in excess of the equivalent of 5&#xD;
             cigarettes per day. For chewing tobacco, one chew is equivalent to approximately 2 to&#xD;
             3 cigarettes, so participants would be limited to 2 or less chews per day.&#xD;
&#xD;
          -  History of sensitivity to prazosin hydrochloride or any of the components in the&#xD;
             formulation of the study products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A0281006</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

